• Strong sales revenue growth of 47% to $8.86m
• Maiden net profit of $433k, up 128.4% from previous period
• Gross margin improved to 61% from 60.2%

During the half year period, Biome Australia Limited experienced strong performance with two quarters of positive EBITDA and reported its maiden net profit. Sales revenue continued its strong growth, with Biome recording a new record of $8.86m for H1, an increase of 47% compared to the previous corresponding period (1H23 $6.02m). The strong sales growth has been driven by Biome's Activated Probiotics, live biotherapeutics (probiotics). Gross margin on sales for the half year period improved to 61% compared to 60.2% (1H23) in the previous corresponding period. The net profit reported for the consolidated entity after providing for income tax amounted to $433k (31 December 2023: Loss of $1,525,383). Excluding Biome's R&D rebate the net profit was $96k for the period. The result reflects the company's strong revenue growth, coupled with control over operating expenses. To date, Biome has reported positive EBITDA over the last four quarters. Biome's distribution footprint in Australia increased by 20% from 5,000 to 6,000 distribution points over the reporting period. Biome's largest distribution channel continues to be Australian community pharmacy, with strong growth in scan sales reported from Biome national partners Terry White Chemmart and Priceline Pharmacy. Biome's practitioner market has also had a strong half with all distributors reporting significant increase in sales volumes. In November 2024, Biome expanded its distribution into Canada - though still at an early stage, the Canadian market is showing very promising signs. Biome's other international markets, UK, Ireland and New Zealand all had strong growth.

The company reported a net profit of $433k for the half-year ended 31 December 2024.